"The two-year program is designed to boost therapies' clinical development"
"The project of Gary W. Miller, PhD, a professor at Columbia University, will assess how to prevent further damage of dopamine-producing neurons by levodopa and its derivatives. Levodopa is the precursor of dopamine and a gold standard therapy for Parkinson’s that effectively reduces early motor symptoms. Evidence suggests the therapy may further damage dopamine-producing neurons due to the overproduction of damaging reactive oxygen species, however."
but wait - there's more.....